New CEOs at CorMedix, Medigene
Plus updates from Elicio, Rejuvenate, Canbridge and more
CorMedix Inc. (NYSE-A:CRMD) named Joseph Todisco as CEO, Donna Ucci as SVP and head of global quality, and promoted EVP of Clinical Operations Liz Hurlburt to an expanded role of EVP of clinical & medical affairs. Todisco and Ucci both joined CorMedix from Amneal Pharmaceuticals Inc. (NYSE:AMRX), where Todisco was CCO and Ucci was VP of global quality management. Additionally, CorMedix said Chief Commercial Officer Tom Nusbickel will leave the company; a replacement was not announced. In conjunction with the management changes, the infectious and inflammatory disease company said it would wind down down its European operations and discontinue distribution of anti-infective therapy Neutrolin in the region. The company resubmitted an NDA to FDA for the treatment, named Defencath in the U.S., in February.
Selwyn Ho will become CEO and executive management board member at Medigene AG (Xetra:MDG1), an immuno-oncology company, on July 25. Ho succeeds Dolores Schendel, who will step down as CEO on July 24 to focus on her role as CSO and head of R&D. Ho joins from Connect Biopharma Holdings Ltd. (NASDAQ:CNTB), where he was CBO. ...